Vigil Neuroscience Inc (VIGL)

May 15, 2025

Barclays PLC Purchases 19,436 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World

May 15, 2025

May 12, 2025

Q2 EPS Estimate for Vigil Neuroscience Increased by Analyst - Defense World

May 12, 2025

May 12, 2025

HC Wainwright Expects Higher Earnings for Vigil Neuroscience - Defense World

May 12, 2025

May 11, 2025

HC Wainwright Has Optimistic Outlook of VIGL FY2029 Earnings - Defense World

May 11, 2025

May 11, 2025

Wedbush Raises Earnings Estimates for Vigil Neuroscience - Defense World

May 11, 2025

May 08, 2025

Vigil Neuroscience Advances Clinical Trials and Financial Stability - TipRanks

May 08, 2025

May 07, 2025

Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year - TipRanks

May 07, 2025

May 07, 2025

Vigil Neuroscience, Inc. SEC 10-Q Report - TradingView

May 07, 2025

May 07, 2025

Vigil Neuroscience Reports Q1 2025 Financial Results and Updates on Clinical Trials for Iluzanebart and VG-3927 - Nasdaq

May 07, 2025

May 07, 2025

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates - GlobeNewswire

May 07, 2025

May 06, 2025

Vigil Neuroscience (NASDAQ:VIGL) Given “Outperform” Rating at Wedbush - Defense World

May 06, 2025

May 05, 2025

Form 8-KCurrent report - ADVFN

May 05, 2025

Apr 27, 2025

Vigil Neuroscience (NASDAQ:VIGL) Upgraded at William Blair - Defense World

Apr 27, 2025

Apr 07, 2025

Vigil Neuroscience stock hits 52-week low at $1.43 - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Vigil Neuroscience stock hits 52-week low at $1.43 By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 02, 2025

Vigil Neuroscience Presents Data on its Small Molecule - GlobeNewswire

Apr 02, 2025

Apr 02, 2025

Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

Vigil presents data on oral small molecule program including VG-3927 - TipRanks

Apr 02, 2025

Apr 02, 2025

Vigil Neuroscience advances Alzheimer’s drug into Phase 2 trials - Investing.com

Apr 02, 2025

Apr 02, 2025

Clinical Data Breakthrough: Vigil's New Alzheimer's Drug Targets Both Aβ and Tau Pathologies - Stock Titan

Apr 02, 2025

Apr 02, 2025

Vigil Neuroscience Reports 2024 Results and Clinical Progress - TipRanks

Apr 02, 2025

Mar 31, 2025

Vigil Neuroscience Files Secondary Stock Shelf - MarketScreener

Mar 31, 2025

Mar 31, 2025

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Decline in Short Interest - Defense World

Mar 31, 2025

Mar 18, 2025

Vigil Neuroscience (VIGL) to Release Earnings on Tuesday - Defense World

Mar 18, 2025

Mar 17, 2025

H.C. Wainwright cuts Vigil Neuroscience stock target to $14 By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Mar 17, 2025

Mar 17, 2025

H.C. Wainwright cuts Vigil Neuroscience stock target to $14 - Investing.com India

Mar 17, 2025

Mar 17, 2025

FY2029 Earnings Forecast for VIGL Issued By Wedbush - Defense World

Mar 17, 2025

Mar 17, 2025

Q1 Earnings Estimate for VIGL Issued By William Blair - Defense World

Mar 17, 2025

Mar 16, 2025

HC Wainwright Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World

Mar 16, 2025

Mar 16, 2025

Wedbush Has Lowered Expectations for Vigil Neuroscience (NASDAQ:VIGL) Stock Price - Defense World

Mar 16, 2025

Mar 14, 2025

Vigil Neuroscience Inc.: Promising Biomarker Data and Strategic Advancements Justify Buy Rating - TipRanks

Mar 14, 2025

Mar 14, 2025

Wedbush Cuts Price Target on Vigil Neuroscience to $13 From $24, Keeps Outperform Rating - Marketscreener.com

Mar 14, 2025

Mar 14, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 14, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com India

Mar 14, 2025

Mar 14, 2025

Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks

Mar 14, 2025

Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data - Investing.com

Mar 13, 2025

Mar 13, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 - Investing.com

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience, Inc. SEC 10-K Report - TradingView

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire

Mar 13, 2025

Mar 13, 2025

Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan

Mar 13, 2025

Mar 13, 2025

SPY ETF News, 3/13/2025 - The Globe and Mail

Mar 13, 2025

Mar 11, 2025

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire

Mar 11, 2025